Animal and Human Studies on PBM for Inflammatory Neurological Disorders
A systematic review found that photobiomodulation (PBM) has anti-inflammatory effects in various neurological models, particularly showing promise in Alzheimer's disease and multiple sclerosis. However, results for Parkinson's disease and major depressive disorder were predominantly negative.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Moderate
- Outcome
- Not reported
Why it matters
This review highlights PBM's potential as a treatment for neuroinflammatory diseases, though clinical research is still in its infancy and inconsistent results suggest caution.
What this does not prove
The clinical efficacy of PBM remains uncertain due to lack of positive outcomes in major studies, necessitating further research to establish treatment parameters and mechanisms.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not applicable
- Controlled
- Not applicable
- Primary endpoint met
- Not applicable
- Relevant MS type
- Not reported
- Publication date
- 2026-10-16
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidencePhotobiomodulation as a regulator of neuroinflammation: mechanistic insights and therapeutic potential in brain disorders. ↗DOI: 10.3389/fneur.2026.1902491
Supporting passages (10)
study designPublication types: Journal Article; Review
subjectsMeSH terms: Humans; Low-Level Light Therapy; Neuroinflammatory Diseases; Animals; Brain Diseases
publication datePublication date: 2026-10-16
findingsPreclinical findings consistently support a multi-target anti-inflammatory effect, whereas clinical investigation remains at an early stage, with encouraging results in Alzheimer's disease and multiple sclerosis but mainly negative data on primary outcomes in Parkinson's disease and major depressive disorder.
limitationsFurther research is needed to optimize treatment parameters, clarify mechanisms of action, and determine clinical efficacy across disease contexts.
peer reviewedPublication types: Journal Article; Review
study phasePublication types: Journal Article; Review
randomizedPublication types: Journal Article; Review
controlledPublication types: Journal Article; Review
primary endpoint metPublication types: Journal Article; Review
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.